Skip to main content
. Author manuscript; available in PMC: 2019 Jul 16.
Published in final edited form as: J Reprod Med. 2010 Sep-Oct;55(9-10):373–381.

Figure 4.

Figure 4.

Univariate sensitivity analysis. This figure demonstrates the most cost-effective strategy over a range of possible maternal adverse health outcomes. If the risk of adverse maternal outcomes is less than 60% of the risk used in our baseline model, then 37+5 weeks with no amniocentesis and steroids is the most cost-effective strategy, and if the risk is greater than 370% of our baseline estimate, then 34+5 weeks with no amniocentesis and steroids is the most cost-effective strategy.